Published in Cancer Res on October 01, 2007
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator. Genes Dev (2013) 1.79
WT1 mutations in T-ALL. Blood (2009) 1.75
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol (2009) 1.55
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
Novel genes associated with colorectal cancer are revealed by high resolution cytogenetic analysis in a patient specific manner. PLoS One (2013) 1.53
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell (2014) 1.51
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
CDC4/FBXW7 and the 'just enough' model of tumourigenesis. J Pathol (2012) 1.50
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell (2012) 1.48
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47
MYC degradation. Cold Spring Harb Perspect Med (2014) 1.42
The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene (2010) 1.41
Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol (2008) 1.35
Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res (2013) 1.33
Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe (2013) 1.27
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res (2008) 1.27
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol (2012) 1.21
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer (2014) 1.21
Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest (2010) 1.17
Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol (2012) 1.17
Evading apoptosis in cancer. Trends Cell Biol (2013) 1.17
Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One (2013) 1.16
Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets (2009) 1.13
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α. Blood (2011) 1.10
The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. Nat Commun (2012) 1.07
The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest (2010) 1.07
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer (2010) 1.05
Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev (2013) 1.05
RORα suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res (2012) 1.04
Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res (2009) 1.04
The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. Mol Cell (2012) 1.03
MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol (2013) 1.01
FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget (2015) 1.01
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet (2013) 1.00
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res (2010) 0.99
FBXW7 is involved in Aurora B degradation. Cell Cycle (2012) 0.98
F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Invest (2015) 0.97
FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. Oncotarget (2013) 0.96
Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol (2011) 0.94
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One (2014) 0.94
Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY) (2013) 0.94
Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem Biophys Res Commun (2012) 0.94
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. Lung Cancer (2013) 0.94
Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn (2010) 0.93
Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther (2010) 0.93
Fbxw7 regulates Notch to control specification of neural precursors for oligodendrocyte fate. Neural Dev (2012) 0.91
Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol (2016) 0.90
Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol (2013) 0.90
FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development. J Pathol (2011) 0.89
In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation? Nat Rev Cancer (2013) 0.89
Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation. Mol Cell Biol (2012) 0.88
FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst (2014) 0.88
Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. PLoS One (2012) 0.88
Recent advances in SCF ubiquitin ligase complex: Clinical implications. Biochim Biophys Acta (2016) 0.85
Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. J Cancer Sci Ther (2012) 0.84
C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. Br J Cancer (2015) 0.84
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget (2015) 0.84
SEL-10/Fbw7-dependent negative feedback regulation of LIN-45/Braf signaling in C. elegans via a conserved phosphodegron. Genes Dev (2012) 0.83
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov (2016) 0.83
MYC is a critical target of FBXW7. Oncotarget (2015) 0.83
FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J (2016) 0.83
Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7. Cell Res (2013) 0.83
MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7. Am J Cancer Res (2016) 0.82
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
A programmable method for massively parallel targeted sequencing. Nucleic Acids Res (2014) 0.82
FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell (2016) 0.82
Genome-wide approaches to systematically identify substrates of the ubiquitin-proteasome pathway. Trends Biotechnol (2010) 0.81
Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood (2011) 0.81
Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond. Curr Opin Cell Biol (2015) 0.81
FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol (2015) 0.81
FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma. Int J Mol Sci (2015) 0.81
Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics (2013) 0.81
Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet (2015) 0.80
Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. Case Rep Oncol Med (2015) 0.80
Self-renewal versus transformation: Fbxw7 deletion leads to stem cell activation and leukemogenesis. Genes Dev (2008) 0.80
SCF-mediated degradation of p100 (NF-κB2): mechanisms and relevance in multiple myeloma. Sci Signal (2012) 0.80
FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. Lab Invest (2015) 0.80
FBW7-mediated ubiquitination and degradation of KLF5. World J Biol Chem (2014) 0.80
Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. Clin Cancer Res (2014) 0.80
Pin1-Nanog expression in human glioma is correlated with advanced tumor progression. Oncol Rep (2013) 0.80
MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression. Int J Clin Exp Med (2015) 0.79
Multiple novel alternative splicing forms of FBXW7α have a translational modulatory function and show specific alteration in human cancer. PLoS One (2012) 0.79
F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation. J Biol Chem (2013) 0.79
Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer (2016) 0.78
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet (2011) 3.97
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet (2008) 3.90
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet (2011) 3.05
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011) 2.91
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 2.72
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science (2009) 2.60
Global analysis of protein sumoylation in Saccharomyces cerevisiae. J Biol Chem (2004) 2.60
Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene (2003) 2.59
Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol (2004) 2.48
LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res (2006) 2.48
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol (2013) 2.33
The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev (2002) 2.33
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptomes. Oncogene (2005) 2.26
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell (2006) 2.22
Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem (2002) 2.20
Improved flow cytometric analysis of the budding yeast cell cycle. Cell Cycle (2002) 2.17
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle (2011) 2.06
Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell (2009) 2.05
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol (2010) 1.93
Circulating tumor cells in metastatic breast cancer--toward individualized treatment? N Engl J Med (2004) 1.89
Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol (2009) 1.89
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype. Hum Mol Genet (2003) 1.85
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res (2007) 1.85
Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet (2008) 1.84
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol (2007) 1.79
SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev (2008) 1.78
SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol (2006) 1.76
Phosphorylation of the septin cdc3 in g1 by the cdc28 kinase is essential for efficient septin ring disassembly. Cell Cycle (2002) 1.76
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst (2003) 1.74
S-phase checkpoint controls mitosis via an APC-independent Cdc20p function. Nat Cell Biol (2003) 1.72
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) 1.71
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol (2005) 1.66
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Nodular lymphoid hyperplasia in common variable immunodeficiency syndrome mimicking familial adenomatous polyposis on endoscopy. Indian J Pathol Microbiol (2009) 1.63
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62